We assessed the tumor‐killing activity of cGAS‐STING pathway inhibitors because high cGAS/STING expression was correlated with poor outcomes in patients with PTCL. The gene discussed is CGAS; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.